Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

Fig. 1

a Growth kinetics of the urothelial cancer cell line RT112 and its gemcitabine-resistant sub-line RT112rGEMCI20 in cell culture. On day 0, both cell lines started with 4000 cells per milliliter. b In vivo growth kinetics of RT112luc and RT112rGEMCI20luc tumors in an orthotopic nu/nu mouse xenograft model as determined by bioluminescence. 10 × 108 photons/s correlate to 10 mm3 tumor volume (21). c Concentration-dependent effects of dasatinib on the viability of the urothelial cancer cell line RT112 and its gemcitabine-resistant sub-line RT112rGEMCI20 as indicated by MTT assay after 120 h of incubation

Back to article page